SVRA
MaterialsSavara Inc
$5.27+0.02 (+0.38%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving SVRA Today?
No stock-specific AI insight has been generated for SVRA yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$1.1B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume1.0M
Avg Volume (10D)—
Shares Outstanding204.9M
SVRA News
20 articles- US High Growth Tech Stocks To WatchYahoo Finance·Apr 27, 2026
- Assessing Savara (SVRA) Valuation After FDA Extends Priority Review For MolgramostimYahoo Finance·Apr 26, 2026
- Savara Announces New Employment Inducement GrantYahoo Finance·Apr 17, 2026
- Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)Yahoo Finance·Apr 15, 2026
- Savara To Present New Data at the American Thoracic Society (ATS) 2026 International ConferenceYahoo Finance·Apr 14, 2026
- Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)Yahoo Finance·Apr 7, 2026
- Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)Yahoo Finance·Mar 30, 2026
- High Growth Tech Stocks To Watch In The US March 2026Yahoo Finance·Mar 26, 2026
- VR Adviser Adds Over 1 Million Savara SharesMotley Fool·Mar 15, 2026
- Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 13, 2026
- Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)Yahoo Finance·Mar 6, 2026
- Savara (SVRA) Is Down 8.0% After FDA Grants Priority Review To MOLBREEVI - What's ChangedYahoo Finance·Mar 6, 2026
- Savara Announces Participation in 2026 Citizens Life Sciences ConferenceYahoo Finance·Mar 4, 2026
- Savara Highlights FDA Priority Review for Molbreevi as Aug. 22 PDUFA Date NearsMarketbeat·Mar 2, 2026
- Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)Yahoo Finance·Feb 20, 2026
- Savara Eyes August PDUFA for MOLBREEVI as FDA BLA Filing Decision Nears, Execs Say at SummitMarketbeat·Feb 15, 2026
- High Growth Tech Stocks To Watch In The US MarketYahoo Finance·Feb 13, 2026
- Savara Insiders Added US$535.6k Of Stock To Their HoldingsYahoo Finance·Feb 9, 2026
- Savara Announces Participation in Upcoming Investor Healthcare ConferencesYahoo Finance·Feb 4, 2026
- A Look At Hercules Capital (HTGC) Valuation After The Expanded Savara Loan AgreementYahoo Finance·Jan 28, 2026
All 20 articles loaded
Price Data
Open$5.22
Previous Close$5.25
Day High$5.34
Day Low$5.18
52 Week High—
52 Week Low—
Fundamentals
Market Cap$1.1B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume1.0M
Avg Volume (10D)—
Shares Outstanding204.9M
About Savara Inc
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—